Sacituzumab Tirumotecan + Tagitanlimab for Advanced NSCLC
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74229–263 (2024).
Google Scholar
Gadgeel, S. et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 381505–1517 (2020).
Google Scholar
Jotte, R. et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J. Thorac. Oncol. 151351–1360 (2020).
Google Scholar
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 3782078–2092 (2018).
Google Scholar
Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 3792040–2051 (2018).
Google Scholar
Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 3812020–2031 (2019).
Google Scholar
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168707–723 (2017).
Google Scholar
Schoenfeld, A. J. et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann. Oncol. 321597–1607 (2021).
Google Scholar
de Castro, G. Jr et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥1% in the KEYNOTE-042 study. J. Clin. Oncol. 411986–1991 (2023).
Google Scholar
Borghaei, H. et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J. Clin. Oncol. 39723–733 (2021).
Google Scholar
Novello, S. et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J. Clin. Oncol. 411999–2006 (2023).
Google Scholar
Brahmer, J. R. et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J. Clin. Oncol. 411200–1212 (2023).
Google Scholar
Paul, S. et al. Cancer therapy with antibodies. Nat. Rev. Cancer 24399–426 (2024).
Google Scholar
Goldenberg, D. M., Stein, R. & Sharkey, R. M. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 928989–29006 (2018).
Google Scholar
Bessede, A. et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 30779–785 (2024).
Google Scholar
Parisi, C., Mahjoubi, L., Gazzah, A. & Barlesi, F. TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treat. Rev. 118102572 (2023).
Google Scholar
Jiang, Y. et al. Progress and innovative combination therapies in Trop-2-targeted ADCs. Pharmaceutocals (Basel) 17652 (2024).
Google Scholar
Cheng, Y. et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol. 12951589 (2022).
Google Scholar
Fang, W. et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study. J. Clin. Oncol. 419114 (2023).
Google Scholar
Fang, W. et al. Abstract CT247: updated efficacy and safety of anti-TROP2 ADC SKB264. Cancer Res. 84CT247 (2024).
Google Scholar
Müller, P. et al. Microtubule-depolymerizing agents used in antibody–drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol. Res. 2741–755 (2014).
Google Scholar
Rios-Doria, J. et al. Antibody–drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 772686–2698 (2017).
Google Scholar
Wei, Q. et al. The promise and challenges of combination therapies with antibody–drug conjugates in solid tumors. J. Hematol. Oncol. 171 (2024).
Google Scholar
Yin, Y. et al. Abstract OT1-03-02: efficacy and safety of SKB264 for previously treat ed metastatic triple negative breast cancer in Phase 2 study. Cancer Res. 83OT1-03-02 (2023).
Google Scholar
D’Amico, L. et al. A novel anti-HER2 anthracycline-based antibody–drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J. Immunother. Cancer 716 (2019).
Google Scholar
Iwata, T. N. et al. A HER2-targeting antibody–drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol. Cancer Ther. 171494–1503 (2018).
Google Scholar
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L. & Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128347–356 (2011).
Google Scholar
Vafa, O. et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65114–126 (2014).
Google Scholar
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 3751823–1833 (2016).
Google Scholar
Lau, S. C. M., Pan, Y., Velcheti, V. & Wong, K. K. Squamous cell lung cancer: current landscape and future therapeutic options. Cancer Cell 401279–1293 (2022).
Google Scholar
Shimizu, T. et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody–drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J. Clin. Oncol. 414678–4687 (2023).
Google Scholar
Heist, R. S. et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J. Clin. Oncol. 352790–2797 (2017).
Google Scholar
Shi, Y. et al. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg. Health West. Pac. 31100617 (2023).
Google Scholar
Lababede, O. & Meziane, M.A. The eighth edition of TNM staging of lung cancer: reference chart and diagrams. Oncologist 23844–848 (2018).
Google Scholar